BOSTON, MA, Bambusa Therapeutics, a biotechnology company, announced the successful closing of its Series Seed financing round, raising approximately $15 million.
BOSTON, MA, Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately $15 million.
The financing round was co-led by BVF Partners L.P. and Dawn Biopharma, a platform controlled by KKR, with participation from Salvia GmbH and INCE Capital. The capital raised will be used to accelerate the development of Bambusa Therapeutics Inc.'s promising pipeline of bispecific antibodies to Phase I clinical studies.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
